Leadership

Leadership

Our leadership, which includes our Executive Management and Board of Directors is accountable for the success and continued innovation at Horizon

Executive Management

Terry Pizzie

Chief Executive Officer

Terry Pizzie

Terry became Chief Executive Officer in May 2018 having joined Horizon Discovery Group in February 2017 as Head of Commercial Operations. He has amassed more than 30 years of commercial experience within the biotechnology tools sector. He started his career with Applied Biosystems in 1988 in a sales role and became Vice President of Europe in 2003. Terry went on to join the Swedish biotechnology firm Biacore in 2005 as SVP Global Commercial Operations and was part of the team that reignited the company’s commercial success, culminating in its acquisition by GE Life Sciences. After a period with Genetix PLC as Director, Global Commercial Operations prior to its acquisition by Danaher, Terry went on to head global sales at Pacific Biosciences.

Terry graduated with a degree in Physiology and Biochemistry from the University of Reading and since then has spent most of his working life focused upon commercial excellence within the sector.

Jayesh Pankhania

Chief Financial Officer

Jayesh Pankhania

Jayesh joined Horizon as CFO in January 2019 and had previously been Interim CFO leading the transformation of the finance function and the development of Horizon’s strategy. He holds an MBA from the London Business School, a degree in Accountancy from the University of East Anglia and is a Chartered Accountant with over 25 years senior finance experience.

Jayesh’s experience includes senior CFO roles at FTSE listed businesses such as Asia Resource Minerals plc, Serco plc and Carillion plc where he led businesses through M&A, implementation of strong corporate and finance governance and development and execution of corporate strategies. In addition, he has led smaller entrepreneurial businesses such as the UK property business of Hines, a real estate developer and Xtera Limited, a provider of subsea telecoms technology. Jayesh qualified with PriceWaterhouseCoopers.

External appointments

Jayesh is Founder and Director of Nisaba Limited and is a Trustee of Ealing Mencap.

Dr Chris Lowe

Head of Research Operations

Chris Lowe

Chris joined Horizon Discovery in 2011 and, prior to leading all research operations within Horizon, led the scientific teams responsible for the development and provision of a range of translational research services to support pre-clinical drug discovery programs. Chris has a background in the genetic analysis of complex disease having obtained his PhD in the field of Medical Genetics from the University of Cambridge where he engaged in research into the genetic causes of Type 1 diabetes in the laboratory of Prof. John Todd, followed by postdoctoral work focusing on Type 2 diabetes and metabolic disease in the laboratory of Prof. Stephen O’Rahilly.

Heather Hayes

Head of Human Resources

Heather Hayes

Heather Hayes VP, Global Head of HR brings significant experience, both operationally and strategically across a range of sectors. The last 8 years being spent in the pharmaceutical industry. Heather led an HR team at Roche responsible for the Development part of the business, she had responsibility for a global workforce, partnering business unit leaders worldwide. Following Roche's purchase of Genentech she was asked to take a global HR role based in San Francisco, where she was responsible for creating alignment, and implementing shared HR strategies for the integrated companies. Heather returned to the UK taking a UK role with R&D in GSK, Stevenage. Prior to Roche and GSK, Heather managed HR strategies and acquisitions in the IT Consultancy, Imaging, Aerospace and Oil industries. Heather graduated from Aberdeen University with an MA in History, and completed her formal qualifications with a postgraduate diploma in Human Resource Management with CIPD membership at Manchester Metropolitan University. Heather joined Horizon in September 2015 and will focus on engagement, development, talent acquisition and recognition.

Kim Nichols

Head of Global Ops

Kim Nichols

Kim joined Horizon Discovery in 2017 with the acquisition of Dharmacon. Kim has been with the Dharmacon business for 18 years in various operational roles under Thermo Fisher Scientific and GE Healthcare.

Prior to joining Dharmacon, Kim spent almost 10 years at the University of Iowa researching and mapping inherited eye diseases. Kim has degrees in Genetics and Business Administration.

Brian Burke

Global Head of Strategy

Brian Burke

Brian joined Horizon in August 2012 as a Business Development Manager and was promoted to Global Head of Strategy during 2018. In this role, he is responsible for driving strategic development and execution across the Horizon business. He works closely with other functions to analyse and impact the wider Horizon opportunity in order to build value more effectively.

Before joining Horizon, Brian worked successfully in a number of commercial and licensing roles with a particular focus on gene editing, bioproduction and next generation sequencing. Prior to moving to industry, he gained a first class honours degree from the University of Glasgow and a PhD from Leeds University.

Board of Directors

Dr Ian Gilham

Non-Executive Chairman

Dr Ian Gilham

Ian is currently Non-Executive Chairman of Genedrive plc, a developer of innovative molecular diagnostic systems and Biosurfit SA which is focused on the development and commercialisation of point-of-care diagnostics. Ian also serves as non-executive Chairman of Elucigene plc. Ian has previously been Chief Executive Officer of Axis-Shield plc and Vice President, Pharmacogenetics and Diagnostics at GSK, as well as holding various positions within Abbott Laboratories

Terry Pizzie

Chief Executive Officer

Terry Pizzie

Terry became Chief Executive Officer in May 2018 having joined Horizon Discovery Group in February 2017 as Head of Commercial Operations. He has amassed more than 30 years of commercial experience within the biotechnology tools sector. He started his career with Applied Biosystems in 1988 in a sales role and became Vice President of Europe in 2003. Terry went on to join the Swedish biotechnology firm Biacore in 2005 as SVP Global Commercial Operations and was part of the team that reignited the company’s commercial success, culminating in its acquisition by GE Life Sciences. After a period with Genetix PLC as Director, Global Commercial Operations prior to its acquisition by Danaher, Terry went on to head global sales at Pacific Biosciences.

Terry graduated with a degree in Physiology and Biochemistry from the University of Reading and since then has spent most of his working life focused upon commercial excellence within the sector.

Jayesh Pankhania

Chief Financial Officer

Jayesh Pankhania

Jayesh joined Horizon as CFO in January 2019 and had previously been Interim CFO leading the transformation of the finance function and the development of Horizon’s strategy. He holds an MBA from the London Business School, a degree in Accountancy from the University of East Anglia and is a Chartered Accountant with over 25 years senior finance experience.

Jayesh’s experience includes senior CFO roles at FTSE listed businesses such as Asia Resource Minerals plc, Serco plc and Carillion plc where he led businesses through M&A, implementation of strong corporate and finance governance and development and execution of corporate strategies. In addition, he has led smaller entrepreneurial businesses such as the UK property business of Hines, a real estate developer and Xtera Limited, a provider of subsea telecoms technology. Jayesh qualified with PriceWaterhouseCoopers.

Mrs Susan Searle

Non-Executive Director

Susan Searle

Susan has over 20 years’ commercial experience as an entrepreneur and innovator. She co-founded Imperial Innovations Group Plc (now part of IP Group Plc),a leading technology venture investment businesses, leading as CEO from 2002 to 2013. During this time the company invested over £120 million, the majority of which was in biotech companies. Susan also holds non-executive director positions with Woodford Patient Capital plc (chair), Mercia Technologies plc (chair), Benchmark Holdings plc (chair of the Remuneration Committee), and QinetiQ Group plc (Audit, Risk and Remuneration Committees). Susan acts as the Senior Independent Director on Horizon’s Board.

Susan has previously held commercial roles with Shell Chemicals, Montech PTY Ltd, and the Bank of Nova Scotia. She has a degree in chemistry from Oxford University.

Dr Susan Galbraith

Non-Executive Director

Susan Galbraith

Dr. Susan Galbraith, currently Senior Vice President and Head of Oncology Innovative Medicines at AstraZeneca, trained as a clinical oncologist, after studying medicine at Manchester and Cambridge Universities, and joins with over 20 years’ combined academic and industry experience.

Susan was previously at Bristol-Myers Squibb, where she was Vice President of Oncology and Clinical Biomarkers from 2008 to 2010. In her roles at both Bristol- Myers Squibb and AstraZeneca, Susan has successfully developed and delivered strategies for the oncology and biomarker groups, resulting in increased success rates, enhanced scientific reputation and high value collaborations. She has also delivered major reorganisations, redesigned governance processes, and contributed to discussions on drug and diagnostic development with regulatory agencies in North America and Europe.

Dr Vishal Gulati

Non-Executive Director

Vishal Gulati

Dr. Vishal Gulati is a specialist healthcare investor in diagnostics, digital healthcare and biotechnology and has served on the boards of companies across Europe, the USA and in India for over a decade. Vishal gained investment management and industry experience at Draper Esprit (formerly DFJ Esprit), Atlas Venture, the Wellcome Trust. Having been a practising physician prior to that, Vishal is able to combine the insights from a technical as well as a financial perspective.

Vishal qualified in medicine in India and received his postgraduate training in Oxford and London as a Rhodes Scholar. In addition to several company boards, Vishal has served on the BioCatalyst awards committee (a UK Government backed £180 million fund for emerging technology companies) an advisor to the Mayor of London’s health commission.

Mr Grahame Cook

Non-Executive Director

Grahame Cook

Grahame is an experienced FTSE and AIM non-executive, with extensive experience as an audit committee chairman. With a background in banking,where he has specialised in the life sciences, pharma and biotech sectors, Grahame has over 20 years’ experience of M&A, equity capital markets and investor relations.Grahame started his career at Arthur Andersen, where he qualified as a chartered accountant and worked within audit and corporate investigations. Subsequent positions include UBS, where he was a member of the global investment banking management committee and global head of equity advisory, and WestLB Panmure, where he was joint Chief Executive Officer. Grahame currently sits on a number of boards, chairing four, including Sinclair Pharma plc and Morphogenesis Inc.Grahame is a graduate of the University of Oxford and remains a member of the ICAEW.

Back to top